<p>Supplementary Table S1. TP53 mutation profiles of human breast cancer cells and HCT116 colon cancer cells</p><p>Name Pos. WT Mut AA MutAA NB WAF1 SUM149 237 ATG ATA Met Ile 123 0.43 MDA-MB-231 280 AGA AAA Arg Lys 78 0.46 MDA-MB-468 273 CGT CAT Arg His 780 1.01 SUM159 158 CGC ins3a Arg InF 1 NA SUM190 317 CAG TAG Gln Stop 25 NA BT-549 249 AGG AGC Arg Ser 34 12.42 HCC70 248 CGG CAG Arg Gln 883 0 T47D 194 CTT TTT Leu Phe 28 14.38 KPL-4 (1, 2) WT MCF-7 WT ZR75-1 WT HCT116 (3) WT HCT116p53-/- (3) p53-/- TP 53 mutation profiles were referred from Handbook of p53 mutation in cell lines (http://p53.free.fr) unless mentioned otherwise. Abbreviations: Pos., codon position (1 to 393); WT, normal base sequence of the codon in which the mutation occurred; Mut, sequence of the mutated codon; ins3a, insertion of 3 bases; AA, wild-type amino acid; MutAA, mutant amino acid; Stop; nonsense mutation; InF, inframe insertion; NB, number of tumors with this particular mutant in the database; WAF1, residual transcriptional activity of mutant p53 on the WAF1 promoter (% compared with wild-type p53). Each p53 mutation listed is a single mutation but not double or more in each cell line.</p><p>References 1. Li C, Lee B, Woodward WA, Ueno NT, Robertson F, Reube J, et al. p53 Mutation in </p><p>Inflammatory Breast Cancer Cell Lines. Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer </p><p>Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. 2009.</p><p>2. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79:707-17. 3. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497-501.</p>